In addition to the use of therapies aimed at reducing N-cadherin activity, studies have investigated whether increasing E-cadherin expression within the primary tumour is a feasible method of reducing the loss of interactions within the epidermal melanin unit, thus preventing cells from entering circulation. The gene discussed is CDH1; the disease is neoplasm.